Webbför 2 dagar sedan · Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and … Webb5 apr. 2024 · Adjuvant or neoadjuvant platinum-based doublet chemotherapy (after surgery and/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy as long as toxicities have resolved to CTCAE grade ≤1 or baseline with the exception of alopecia and peripheral neuropathy.
Molecular Pathways: The Immunogenic Effects of Platinum-Based …
WebbPlatinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used … WebbThe platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose-limiting side effects (also referred to as adverse effects/events). In total, a cancer patient can experience any combination of around 40 specific side effects. hempcrete austin
NSCLC, long-term survival with neoadjuvant immunotherapy
Webb15. First-line treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma in combination with fluoropyrimidine- and platinum-based chemotherapy 16. Neoadjuvant treatment of adult patients with resectable (tumors ≥ 4cm or node positive) non-small cell lung cancer in combination with platinum-doublet ... Webb20 nov. 2024 · Background Chemotherapy can improve the survival of patients with advanced gastric cancer. However, whether triplet chemotherapy can further improve the survival of patients with advanced gastric cancer compared with doublet chemotherapy remains controversial. This study reviewed and updated all published and eligible … Webb1293P - KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with platinum doublet chemotherapy as first-line (1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations. Date 16 Sep 2024. Session ... KN046 combined with platinum-based chemotherapy is well tolerated and has demonstrated … langhorne pharmacy pa